Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831788 | 1.00 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL8069973 | 0.82 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL8069970 | 0.82 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL11134387 | 0.79 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL6539016 | 0.79 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL6539020 | 0.79 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2PDE4APDE4B | |
| SCHEMBL14399728 | 0.77 | TSHR (0.38) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL5447543 | 0.76 | DGAT1 (0.34) | CA14 | |
| SCHEMBL2647184 | 0.76 | NPSR1 (0.50) | HCAR2CA14 | |
| SCHEMBL2647130 | 0.76 | NPSR1 (0.50) | HCAR2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0326389-B1 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES (JP) | 1996-09-11 | — | — | EP | claimed |
| US-4935516-A | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | claimed |
| EP-0326389-A2 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1989-08-02 | — | — | EP | claimed |
| US-10781177-B2 | Pyridine compound and use thereof | NIPPON SODA CO., LTD. (JP) | 2020-09-22 | — | — | US | disclosed |
| US-20190071403-A1 | PYRIDINE COMPOUND AND USE THEREOF | NIPPON SODA CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| EP-3428151-A1 | PYRIDINE COMPOUND AND USE THEREOF | Nippon Soda Co., Ltd. (JP) | 2019-01-16 | — | — | EP | disclosed |
| EP-3016961-B1 | NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES | BOEHRINGER INGELHEIM INT (DE) | 2017-11-15 | — | — | EP | disclosed |
| EP-3016961-A1 | NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES | Boehringer Ingelheim International GmbH (DE) | 2016-05-11 | — | — | EP | disclosed |
| US-9029540-B2 | Ruthenium catalysts and their use for asymmetric reduction of ketones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| WO-2015002769-A1 | NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | WO | disclosed |
| US-20150005500-A1 | NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-01 | — | — | US | disclosed |
| US-6069148-A | ANTICHOLESTEROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-30 | — | — | US | disclosed |
| US-6063788-A | TREATMRNT OF ARTHERIOSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
| EP-0970053-A1 | 5-OXYSUBSTITUTED CHINOLINES AND THEIR USE AS CHOLESTEROL ESTER TRANSFER PROTEINS INHIBITORS | BAYER AG (DE) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998039299-A1 | 5-OXYSUBSTITUTED CHINOLINES AND THEIR USE AS CHOLESTEROL ESTER TRANSFER PROTEINS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-09-11 | — | — | WO | disclosed |
| EP-0825185-A1 | Pyridine fused to a bicyclic ring | BAYER AG (DE) | 1998-02-25 | — | — | EP | disclosed |
| EP-0818448-A1 | Cycloalkano-pyridine as CETP inhibitors | BAYER AG (DE) | 1998-01-14 | — | — | EP | disclosed |
| EP-0326389-B1 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-4935516-A | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| EP-0326389-A2 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781177-B2 | Pyridine compound and use thereof | NOX1, NOXO1, NOX4 | HCAR2 2929/4885KEAP1 22/4885NFE2L2 1331/4885 |
| US-20190071403-A1 | PYRIDINE COMPOUND AND USE THEREOF | NOX1, NOXO1, NOX4 | HCAR2 2929/4885KEAP1 22/4885NFE2L2 1331/4885 |
| US-20150005500-A1 | NOVEL RUTHENIUM CATALYSTS AND THEIR USE FOR ASYMMETRIC REDUCTION OF KETONES | PDHB, CYP2E1, PDK1 | HCAR2 2404/4885KEAP1 638/4885NFE2L2 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.